Cargando…

A Multi-Institutional Analysis of Prostate Cancer Patients With or Without 68Ga-PSMA PET/CT Prior to Salvage Radiotherapy of the Prostatic Fossa

INTRODUCTION: 68Ga-PSMA PET/CT is associated with unprecedented sensitivity for localization of biochemically recurrent prostate cancer at low PSA levels prior to radiotherapy. Aim of the present analysis is to examine whether patients undergoing postoperative, salvage radiotherapy (sRT) of the pros...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schmidt-Hegemann, Nina-Sophie, Zamboglou, Constantinos, Thamm, Reinhard, Eze, Chukwuka, Kirste, Simon, Spohn, Simon, Li, Minglun, Stief, Christian, Bolenz, Christian, Schultze-Seemann, Wolfgang, Bartenstein, Peter, Prasad, Vikas, Ganswindt, Ute, Grosu, Anca-Ligia, Belka, Claus, Mayer, Benjamin, Wiegel, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517476/ https://www.ncbi.nlm.nih.gov/pubmed/34660290 http://dx.doi.org/10.3389/fonc.2021.723536

Ejemplares similares

Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis
por: Schmidt Hegemann, Nina-Sophie, et al.
Publicado: (2020)

PSMA-positive nodal recurrence in prostate cancer: Salvage radiotherapy is superior to salvage lymph node dissection in retrospective analysis
por: Schmidt-Hegemann, Nina-Sophie, et al.
Publicado: (2020)

Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy
por: Schmidt-Hegemann, Nina-Sophie, et al.
Publicado: (2017)

Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy
por: Schmidt-Hegemann, Nina-Sophie, et al.
Publicado: (2018)

Patient-Reported and Oncological Outcomes of Salvage Therapies for PSMA-Positive Nodal Recurrent Prostate Cancer: Real-Life Experiences and Implications for Future Trial Design
por: Kretschmer, Alexander, et al.
Publicado: (2021)

Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy
por: Rogowski, Paul, et al.
Publicado: (2021)

Distribution of prostate nodes: a PET/CT-derived anatomic atlas of prostate cancer patients before and after surgical treatment
por: Hegemann, Nina-Sophie, et al.
Publicado: (2016)

DNA-methylation and genomic copy number in primary tumors and corresponding lymph node metastases in prostate cancer from patients with low and high Gleason score
por: Unger, Kristian, et al.
Publicado: (2023)

Combining (68)Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study
por: Kirste, Simon, et al.
Publicado: (2021)

Hypofractionated radiotherapy for prostate cancer
por: Hegemann, Nina-Sophie, et al.
Publicado: (2014)

Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer
por: Rogowski, Paul, et al.
Publicado: (2021)

PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial
por: Zamboglou, Constantinos, et al.
Publicado: (2021)

Development of PSMA-PET-guided CT-based radiomic signature to predict biochemical recurrence after salvage radiotherapy
por: Spohn, Simon K. B., et al.
Publicado: (2023)

PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml
por: Solomonidou, Nantia, et al.
Publicado: (2023)

The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy—a multicenter retrospective analysis
por: Spohn, Simon K. B., et al.
Publicado: (2022)

Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy
por: Oehus, Ann-Kathrin, et al.
Publicado: (2020)

Risk Factors for Biochemical Recurrence After PSMA-PET-Guided Definitive Radiotherapy in Patients With De Novo Lymph Node-Positive Prostate Cancer
por: Spohn, Simon K.B., et al.
Publicado: (2022)

Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET–Based Salvage Radiotherapy for Recurrent Prostate Cancer
por: Zamboglou, Constantinos, et al.
Publicado: (2023)

Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [(68)Ga]PSMA-PET-guided metastasis-directed therapy
por: Vogel, Marco M. E., et al.
Publicado: (2020)

Comparison of Manual and Semi-Automatic [(18)F]PSMA-1007 PET Based Contouring Techniques for Intraprostatic Tumor Delineation in Patients With Primary Prostate Cancer and Validation With Histopathology as Standard of Reference
por: Spohn, Simon K. B., et al.
Publicado: (2020)

Radiotherapy of oligometastatic prostate cancer: a systematic review
por: Rogowski, Paul, et al.
Publicado: (2021)

Intra-fraction motion of the prostate is not increased by patient couch shifts
por: Ballhausen, Hendrik, et al.
Publicado: (2016)

Interobserver variability, detection rate, and lesion patterns of (68)Ga-PSMA-11-PET/CT in early-stage biochemical recurrence of prostate cancer after radical prostatectomy
por: Miksch, Jonathan, et al.
Publicado: (2020)

A comparative assessment of prostate positioning guided by three-dimensional ultrasound and cone beam CT
por: Li, Minglun, et al.
Publicado: (2015)

Impact of a low FODMAP diet on the amount of rectal gas and rectal volume during radiotherapy in patients with prostate cancer – a prospective pilot study
por: Schaefer, Christian, et al.
Publicado: (2020)

Intraindividual comparison between (68)Ga-PSMA-PET/CT and mpMRI for intraprostatic tumor delineation in patients with primary prostate cancer: a retrospective analysis in 101 patients
por: Spohn, Simon, et al.
Publicado: (2020)

Isotropic Expansion of the Intraprostatic Gross Tumor Volume of Primary Prostate Cancer Patients Defined in MRI—A Correlation Study With Whole Mount Histopathological Information as Reference
por: Kramer, Maria, et al.
Publicado: (2020)

Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer—Combination Strategies
por: Arbuznikova, Daria, et al.
Publicado: (2023)

Choline PET based dose-painting in prostate cancer - Modelling of dose effects
por: Niyazi, Maximilian, et al.
Publicado: (2010)

Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial
por: Holzgreve, Adrien, et al.
Publicado: (2023)

Risk of second cancer following radiotherapy for prostate cancer: a population-based analysis
por: Hegemann, Nina-Sophie, et al.
Publicado: (2017)

Ultrahypofractionation of localized prostate cancer: Statement from the DEGRO working group prostate cancer
por: Wolf, Frank, et al.
Publicado: (2020)

Results from extended lymphadenectomies with [(111)In]PSMA-617 for intraoperative detection of PSMA-PET/CT-positive nodal metastatic prostate cancer
por: Jilg, Cordula A., et al.
Publicado: (2020)

The dose distribution in dominant intraprostatic tumour lesions defined by multiparametric MRI and PSMA PET/CT correlates with the outcome in patients treated with primary radiation therapy for prostate cancer
por: Zamboglou, Constantinos, et al.
Publicado: (2018)

Elective nodal radiotherapy with a gapless radiation field junction for oligorecurrent prostate cancer after previous radiotherapy
por: Li, Minglun, et al.
Publicado: (2022)

Uncovering the invisible—prevalence, characteristics, and radiomics feature–based detection of visually undetectable intraprostatic tumor lesions in (68)GaPSMA-11 PET images of patients with primary prostate cancer
por: Zamboglou, Constantinos, et al.
Publicado: (2020)

Changes of Radiation Treatment Concept Based on (68)Ga-PSMA-11-PET/CT in Early PSA-Recurrences After Radical Prostatectomy
por: Bottke, Dirk, et al.
Publicado: (2021)

Personalized [177Lu]Lutetium-PSMA Therapy for Patients with Pre-Treated Castration-Resistant Prostate Cancer: A Single Institution Experience from a Comprehensive Cancer Centre
por: Thaiss, Wolfgang, et al.
Publicado: (2023)

Toxicity and quality of life after choline-PET/CT directed salvage lymph node dissection and adjuvant radiotherapy in nodal recurrent prostate cancer
por: Jilg, Cordula A, et al.
Publicado: (2014)

Incidental Finding of a PSMA-Positive Pancreatic Cancer in a Patient Suffering from a Metastasized PSMA-Positive Prostate Cancer
por: Sirtl, Simon, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0967oaluq9a2pq8ke49f8qmleg